R&D

1. EUROSTARS: PREVAIL

Preclinical development of novel ERRalpha inhibitors for treatment of Triple Negative Breast Cancer. The PREVAIL project will deliver a first-in-class targeted therapeutic for treatment of triple negative breast cancer (TNBC). 

2. SEAL OF EXCELLENCE

Next generation of targeted dendritc cell vaccine for cancer treatment, a therapeutic cancer vaccine technology platform. We are actively seeking partners in the pharmaceutical industry and clinical centres in order to co-develop our patented vaccine technology.